News
Season Greetings - 2022
A very happy holiday season from the whole AMAL team, and a great start into 2022 !
AMAL Therapeutics to publish research outcomes in Cancers
Geneva, Switzerland, December 3, 2021 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website.
AMAL Therapeutics to publish latest findings of its in vivo research team, in collaboration with Medical University of Innsbruck, on Nature Communication website
Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the Medical University of Innsbruck, is online on the Nature Communication website. The results show that combinatorial treatment with a protein-based cancer vaccine and an oncolytic virus elicits a potent immune response resulting in long lasting anti-tumoral efficacy in different tumor models, highlighting the potential for cancer treatment.
AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology
Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website.
AMAL Therapeutics to publish R&D outcomes in Cancers
Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website.